CONCLUSIONS
Sarcopenia has been shown to be a risk factor for the development of post-surgical complications in patients with hepatoblastoma. It also seems to have a negative impact on survival. Measurement of tPMA at baseline cross-sectional imaging as a predictor of the sarcopenia status should be considered as part of the initial study in children with hepatoblastoma. When detected, treatment of the sarcopenia should be a key point in children with hepatoblastoma.